16 completed, 4 recruiting, 1 terminated, 1 unknown. 23 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 23 | Completed 16, Recruiting 4, Terminated 1, Unknown 1, Withdrawn 1 |
| Phase 1 | 4 | Completed 2, Recruiting 2 |
Follow Chromosome Aberrations: new trials by email Literature Review of Chromosome Aberrations trials Research Report on Chromosome Aberrations
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Single-arm, Open-label Study of Olverembatinib, CD3/CD19 Bispecific T-cell Engager, and Chidamide in Patients With Newly Diagnosed Ph+ALL Prednisone, Olverembatinib, Blinatumomab, Chidamide - Acute Lymphoblastic Leukemia, Philadelphia Chromosome | Phase 2 | Recruiting | Nanfang Hospital, Southern Medical University | 67 | 2024-02-01 | 2024-01-24 |
| Pediatric-Inspired Chemotherapy Plus Tyrosine Kinase Inhibitor in Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Dasatinib, Ponatinib, Berlin-Frankfurt-Münster Chemotherapy - Acute Lymphoblastic Leukemia | Phase 2 | Withdrawn | University of Michigan Rogel Cancer Center | 2024-01-01 | 2024-02-22 | |
| A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer VLS-1488 - Advanced Solid Tumor, High Grade Serous Adenocarcinoma of Ovary | Phase 1 / Phase 2 | Recruiting | Volastra Therapeutics, Inc. | 200 | 2023-10-18 | 2025-11-04 |
| MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies Fludarabine, Busulfan, Melphalan - Hematologic Malignancy, Acute Leukemia | Phase 2 | Recruiting | Masonic Cancer Center, University of Minnesota | 70 | 2023-05-11 | 2026-04-06 |
| CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies CD19/CD22-CAR-transduced T cells, cyclophosphamide, fludarabine - B-NHL, B-Non Hodgkin Lymphoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 130 | 2022-12-28 | 2026-10-26 |
| Study of Azacitidine，Venetoclax，and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients Azacitidine, Venetoclax, Flumatinib - Philadelphia Chromosome, Acute Myeloid Leukemia | Phase 2 | Completed | The First Affiliated Hospital of Soochow University | 20 | 2022-05-01 | 2024-04-25 |
| Low-Dose Ketamine in Children With ADNP Syndrome Ketamine - ADNP Syndrome | Phase 1 / Phase 2 | Completed | Alexander Kolevzon | 10 | 2020-08-19 | 2023-07-07 |
| Study of Inotuzumab Ozogamicin Combined to Chemotherapy in Older Patients With Philadelphia Chromosome-negative CD22+ B-cell Precursor ALL Inotuzumab ozogamicin (INO) - Acute Lymphoblastic Leukemia (ALL) - Philadelphia Chromosome (Ph)-Negative CD22+ B-cell Precursor (BCP) | Phase 2 | Completed | Versailles Hospital | 131 | 2017-12-28 | 2026-06-22 |
| Dasatinib Combined With Chemotherapy in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia Dasatinib, prednisone, cyclophosphamide - Acute,Leukemia, Lymphoid | Phase 2 | Completed | Institute of Hematology & Blood Diseases Hospital, China | 30 | 2015-08-01 | 2026-02-11 |
| TKI Therapy Based on Molecular Monitoring in Allogeneic-HSCT Recipients With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia TKIs - Philadelphia Chromosome Positive Acute Lymphocytic Leukemia, Stem Cell Transplantation | Phase 2 | Unknown | Nanfang Hospital, Southern Medical University | 80 | 2013-06-01 | 2017-11-08 |
| Study of Frontline Dasatinib Plus Chemotherapy in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (PH+ALL) Dasatinib - Philadelphia Positive Acute Lymphoblastic Leukemia | Phase 2 | Completed | Goethe University | 19 | 2011-11-01 | 2022-01-26 |
| Pegasys in Patients With Chronic Myeloid Leukemia (CML) PEG-IFNá-2a - Leukemia | Phase 2 | Terminated | M.D. Anderson Cancer Center | 2 | 2011-10-01 | 2015-05-04 |
| Randomized Study Comparing the Effect of Dasatinib and Imatinib on Malignant Stem Cells in Chronic Myeloid Leukemia Imatinib, Dasatinib - Chronic Myeloid Leukemia | Phase 2 | Completed | Norwegian University of Science and Technology | 46 | 2009-03-01 | 2017-09-25 |
| Philadelphia Chromosome Positive CML Patients Without Optimal Response or Tolerance to Bcr-Abl TKI Radotinib - Leukemia, Leukemia, Myeloid | Phase 1 / Phase 2 | Completed | Il-Yang Pharm. Co., Ltd. | 85 | 2008-07-01 | 2018-08-29 |
| Effects of Methylphenidate on Cellular Abnormalities in Children With Attention Deficit Hyperactivity Disorder (ADHD) Extended Release Methylphenidate (Ritalin LA ) plus Behavior Therapy, Behavior Therapy - Attention Deficit Hyperactivity Disorder | Phase 2 | Completed | Novartis | 142 | 2006-11-01 | 2011-05-17 |
| Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias Bosutinib - Chronic Myeloid Leukemia | Phase 2 | Completed | Pfizer | 571 | 2006-01-18 | 2017-07-27 |
| Safety and Efficacy of Imatinib Added to Chemotherapy in Treatment of Ph+ Acute Lymphoblastic Leukemia in Children Standard chemotherapy + Imatinib - Acute Lymphoblastic Leukemia, Philadelphia Chromosome | Phase 2 | Completed | Rennes University Hospital | 49 | 2005-12-01 | 2023-05-24 |
| Imatinib Mesylate With Vincristine and Dexamethasone in Acute Lymphoblastic Leukemias With BCR-ABL Positive Imatinib mesylate, Interferon, Vincristine - Leukemia, Lymphocytic, Acute, Philadelphia Chromosome | Phase 2 | Completed | Assistance Publique - Hôpitaux de Paris | 55 | 2004-12-01 | 2011-10-05 |
| Study of Imatinib-Combined Chemotherapy for BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL) imatinib, cyclophosphamide, daunorubicin - Acute Lymphoblastic Leukemia | Phase 2 | Completed | Japan Adult Leukemia Study Group | 100 | 2002-09-01 | 2008-11-14 |
| Protein-Tyrosine Kinase Inhibitor (STI571) for Treatment of Patients With Ph+ Chronic Myeloid Leukemia STI571 - Chronic Myeloid Leukemia | Phase 2 | Completed | University of Bologna | 200 | 2000-08-01 | 2007-08-03 |
Showing 20 of 23. Sign in to see all of them.
Philadelphia Chromosome (19) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (14) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (10) · Leukemia (5) · Leukemia, Myeloid, Acute (4) · Neoplasm, Residual (3) · Blast Crisis (2) · Anemia, Refractory, with Excess of Blasts (1) · Attention Deficit Disorder with Hyperactivity (1) · Burkitt Lymphoma (1) · Chromosomal Instability (1) · Chromosome 7, monosomy (1) · Chromosome Disorders (1) · Endometrial Neoplasms (1)
Pathologic Processes (23) · Pathological Conditions, Signs and Symptoms (23) · Neoplasms (21) · Neoplasms by Histologic Type (21) · Hemic and Lymphatic Diseases (20) · Hematologic Diseases (19) · Translocation, Genetic (19) · Leukemia (15) · Immune System Diseases (14) · Immunoproliferative Disorders (14) · Leukemia, Lymphoid (14) · Lymphatic Diseases (14) · Lymphoproliferative Disorders (14) · Bone Marrow Diseases (11)
Imatinib Mesylate (8) · Cyclophosphamide (4) · Dasatinib (4) · Cytarabine (3) · Dexamethasone (3) · Methotrexate (3) · Vincristine (3) · Daunorubicin (2) · Prednisone (2) · fludarabine (2) · peginterferon alfa-2a (2) · 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamide (1) · Azacitidine (1) · Behavior Therapy (1) · Busulfan (1)
Novartis Pharmaceuticals (3) · Nanfang Hospital, Southern Medical University (2) · Alexander Kolevzon (1) · Assistance Publique - Hôpitaux de Paris (1) · Goethe University (1) · Il-Yang Pharm. Co., Ltd. (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · Japan Adult Leukemia Study Group (1) · M.D. Anderson Cancer Center (1) · Masonic Cancer Center, University of Minnesota (1) · National Cancer Institute (NCI) (1) · Norwegian University of Science and Technology (1) · Novartis (1) · Pfizer (1) · Rennes University Hospital (1)
United States (11) · France (6) · China (5) · Germany (5) · Italy (4) · United Kingdom (3) · Finland (2) · India (2) · Norway (2) · South Korea (2) · Sweden (2) · Argentina (1) · Australia (1) · Austria (1) · Brazil (1)
Alexander Kolevzon, MD (1) · Alfonso Quintas-Cardama, MD (1) · Andrea Biondi, MD (1) · Bengt Simonsson, MD, PhD (1) · Congcong Wang (1) · Fumihiko Hayakawa, MD (1) · Henrik Hjorth-Hansen, MD, PhD (1) · Hongsheng Zhou, M.D., Ph.D (1) · IL-yang Pharm (1) · Ingunn Dybedal, MD, PhD (1) · Jiali Yao (1) · Jianxiang Wang, Dr. (1) · Johan Richter, MD, PhD (1) · Kimmo Porkka, MD, PhD (1)
PMID 15315963, PMID 16344315, PMID 18223280, PMID 21865346, PMID 22036634, PMID 22371878, PMID 22898679, PMID 23116602, PMID 23328954, PMID 24345751, PMID 24705186, PMID 24711212, PMID 24919837, PMID 25082346, PMID 25761894, PMID 27045164, PMID 27531525, PMID 29072772, PMID 29773593, PMID 30501871, PMID 33204013, PMID 33242441, PMID 33858040, PMID 34120773, PMID 34673442, PMID 35235189, PMID 39418626
2005 (4), 2008 (1), 2016 (1)